Abstract

T cells correlated with improved progression-free survival following ICB. Our findings argue for the development of therapies aimed at maintaining the expression of CD226.

Authors	Braun, Matthias; Aguilera, Amelia Roman; Sundarrajan, Ashmitha; Corvino, Dillon; Stannard, Kimberley; Krumeich, Sophie; Das, Indrajit; Lima, Luize G; Meza Guzman, Lizeth G; Li, Kunlun; Li, Rui; Salim, Nazhifah; Jorge, Maria Villancanas; Ham, Sunyoung; Kelly, Gabrielle; Vari, Frank; Lepletier, Ailin; Raghavendra, Ashwini; Pearson, Sally; Madore, Jason; Jacquelin, Sebastien; Effern, Maike; Quine, Brodie; Koufariotis, Lambros T; Casey, Mika; Nakamura, Kyohei; Seo, Eun Y; Hölzel, Michael; Geyer, Matthias; Kristiansen, Glen; Taheri, Touraj; Ahern, Elizabeth; Hughes, Brett G M; Wilmott, James S; Long, Georgina V; Scolyer, Richard A; Batstone, Martin D; Landsberg, Jennifer; Dietrich, Dimo; Pop, Oltin T; Flatz, Lukas; Dougall, William C; Veillette, André; Nicholson, Sandra E; Möller, Andreas; Johnston, Robert J; Martinet, Ludovic; Smyth, Mark J; Bald, Tobias
Journal	IMMUNITY
Pages	805-823.e15
Volume	53
Date	1/10/2020
Grant ID
Funding Body	BioBank Core Facility of the University Hospital Bonn, Germany
URL	http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016/j.immuni.2020.09.010
	Download Article